Jakob Schmidt Jensen1, Julie Thor Christensen1, Katrin Håkansson2, Martin Zamani1, Ivan R Vogelius2, Johan Löfgren3, Babara Malene Fischer3,4, Jeppe Friborg2, Christian von Buchwald1, Jacob Høygaard Rasmussen5. 1. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 2. Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 3. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 4. The PET Centre, School of Biomedical Engineering and Imaging Sciences KCL St Thomas' Hospital, Bridge Road London, Westminster, SE1 7EH, UK. 5. Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Jacob.hoeygaard.rasmussen.01@regionh.dk.
Abstract
BACKGROUND: The purpose of this study was to investigate if FDG uptake metrics in primary tumor and lymph node metastases in patients with oropharyngeal squamous cell carcinoma (OPSCC) has a prognostic value beyond UICC8 staging in a multiple endpoint model. METHODS: Patients with OPSCC treated with primary radiotherapy at Rigshospitalet in the period 2010-2017 were included. All patients had a pretreatment FDG PET/CT scan performed. Four cause-specific Cox regression models were built for the hazard ratios (HR) of recurrence in T-, N-, M-site, and death with no evidence of disease (NED), respectively. The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes. A competing risk analysis was performed and absolute risk estimates were estimated using the Aalen-Johansen method. RESULTS: Overall, 441 patients were included. Thirty-four patients had T-site recurrence, 31 N-site recurrence, 32 M-site recurrence, and 52 patients had death NED as event. Nodal FDG uptake had a significant impact on N- and M-site recurrence, with HRs of 2.13 (CI 1.20-3.77) and 2.18 (CI 1.16-4.10). The individual prognostication of absolute risk of the four events for any given patient can be assessed in the online tool (https://rasmussen.shinyapps.io/OPSCCmodelFDG_PET/). CONCLUSION: High nodal FDG uptake increases the risk of N- and M-site recurrence in patients with OPSCC in a competing risk scenario. The reported results are available in an easy applicable online tool and can help identify relevant candidates for future trials testing treatment approaches.
BACKGROUND: The purpose of this study was to investigate if FDG uptake metrics in primary tumor and lymph node metastases in patients with oropharyngeal squamous cell carcinoma (OPSCC) has a prognostic value beyond UICC8 staging in a multiple endpoint model. METHODS:Patients with OPSCC treated with primary radiotherapy at Rigshospitalet in the period 2010-2017 were included. All patients had a pretreatment FDG PET/CT scan performed. Four cause-specific Cox regression models were built for the hazard ratios (HR) of recurrence in T-, N-, M-site, and death with no evidence of disease (NED), respectively. The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes. A competing risk analysis was performed and absolute risk estimates were estimated using the Aalen-Johansen method. RESULTS: Overall, 441 patients were included. Thirty-four patients had T-site recurrence, 31 N-site recurrence, 32 M-site recurrence, and 52 patients had death NED as event. Nodal FDG uptake had a significant impact on N- and M-site recurrence, with HRs of 2.13 (CI 1.20-3.77) and 2.18 (CI 1.16-4.10). The individual prognostication of absolute risk of the four events for any given patient can be assessed in the online tool (https://rasmussen.shinyapps.io/OPSCCmodelFDG_PET/). CONCLUSION: High nodal FDG uptake increases the risk of N- and M-site recurrence in patients with OPSCC in a competing risk scenario. The reported results are available in an easy applicable online tool and can help identify relevant candidates for future trials testing treatment approaches.
Authors: Daniel Tiedemann; Kathrine Kronberg Jakobsen; Christian von Buchwald; Christian Grønhøj Journal: Head Neck Date: 2018-12-23 Impact factor: 3.147
Authors: Anvesh R Kompelli; Patrick Morgan; Hong Li; William Harris; Terry A Day; David M Neskey Journal: Otolaryngol Head Neck Surg Date: 2018-12-11 Impact factor: 3.497
Authors: John R de Almeida; Ryan Li; J Scott Magnuson; Richard V Smith; Eric Moore; Georges Lawson; Marc Remacle; Ian Ganly; Dennis H Kraus; Marita S Teng; Brett A Miles; Hilliary White; Umamaheswar Duvvuri; Robert L Ferris; Vikas Mehta; Krista Kiyosaki; Edward J Damrose; Steven J Wang; Michael E Kupferman; Yoon Woo Koh; Eric M Genden; F Christopher Holsinger Journal: JAMA Otolaryngol Head Neck Surg Date: 2015-12 Impact factor: 6.223
Authors: Maura L Gillison; Qiang Zhang; Richard Jordan; Weihong Xiao; William H Westra; Andy Trotti; Sharon Spencer; Jonathan Harris; Christine H Chung; K Kian Ang Journal: J Clin Oncol Date: 2012-05-07 Impact factor: 44.544
Authors: Jason C Fleming; Jeongmin Woo; Karwan Moutasim; Massimiliano Mellone; Steven J Frampton; Abbie Mead; Waseem Ahmed; Oliver Wood; Hollie Robinson; Matthew Ward; Christopher H Woelk; Christian H Ottensmeier; Emma King; Dae Kim; Jeremy P Blaydes; Gareth J Thomas Journal: Br J Cancer Date: 2019-01-17 Impact factor: 7.640